Mechanism of action Cilostazol exhibits greater selectivity than dipyridamole as an inhibitor of PDE3A. The drug does not affect the other PDEs (PDEs 1, 2, or 4). Cilostazol reversibly inhibit platelet aggregation induced by a number of stimuli, such as thrombin, ADP, collagen, or stress from...
Accumulation of abnormal protein aggregates is a common pathological finding in a variety of neurodegenerative disorders, including Alzheimer disease (AD) and Parkinson disease (PD)1,2. While initial studies focused on the mechanism by which protein aggregates are generated in a particular neurodegenera...
It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions.|Cilostazol is a Phosphodiesterase 3 Inhibitor. The mechanism of action of cilostazol is as a Phosphodiesterase 3 ...
This analysis vastly expands the racial and demographic profile of the evaluated study population and the impact of cilostazol on a more diverse and generalizable patient population. The mechanism of action of cilostazol on arterial patency and enhanced limb salvage in patients with PAD undergoing ...
In this review, we discuss the mechanism of action of cilostazol and evaluate the efficacy and safety of the drug based on the results of clinical trials. Furthermore, we comprehensively explore the role of cilostazol in the prevention and treatment of atherosclerosis. 2. Limitations of Aspirin ...
Article Intravenous Administration of Cilostazol Nanoparticles Ameliorates Acute Ischemic Stroke in a Cerebral Ischemia/Reperfusion-Induced Injury Model Noriaki Nagai, Chiaki Yoshioka, Yoshimasa Ito *, Yoshinori Funakami, Hiroyuki Nishikawa and Atsufumi Kawabata Received: 1 September 2015; Accepted: 3 ...